Skip to content
Open access

LPR-1-Mediated targeted intranasal delivery of lentinan-loaded polymeric nanocarriers for GBM therapy via modulation of apoptotic signalling.

Aug 2026 · Nanomedicine · Vol 21, pp. 1-20 · 0 citations · 19 references
Medicine

TL;DR

LRP-1-targeted LRP-1-targeted Lf-LNT-PEG-CS-NCs significantly enhanced intranasal brain delivery, cellular uptake, and apoptotic activity of LNT, demonstrating a promising noninvasive platform for targeted GBM therapy.

Abstract

Aim

To develop and evaluate a lactoferrin (Lf)-functionalized polyethylene glycol (PEG)-grafted chitosan (CS) nanocarriers (NCs) for low-density lipoprotein receptor-related protein-1 (LRP1)-mediated intranasal delivery of lentinan (LNT) to enhance brain targeting and anti-glioblastoma (GBM) efficacy.

Materials And Methods

Lf-LNT-PEG-CS-NCs were prepared, optimized, and characterized for particle size, entrapment efficiency, coating efficiency, and release behavior. Ex vivo permeation, cellular uptake, cytotoxicity, apoptosis, pharmacokinetic, and biodistribution studies were performed using U87 MG cells and Wistar rats.

Results

The optimized NCs exhibited a particle size of 205.3 ± 11 nm, entrapment efficiency of 71.52 ± 0.98%, and coating efficiency of 92.42 ± 0.94%, with sustained drug release for 36 h. The permeation increased by 2.86-fold, while cellular uptake reached 78.38 ± 3.76%. Treatment significantly reduced U87 MG cell viability (84.21 ± 2.75% inhibition) and induced apoptosis with 64.55 ± 2.28% G0/G1 arrest, accompanied by reduced COX-2 (55.81 ± 2.91%) and Bcl-2 (59.65 ± 1.95%) expression and increased caspase-3 (73.10 ± 2.91%). Intranasal administration achieved a CSF Cmax of 46.72 ± 3.78 μg/mL and brain accumulation of 42.83 ± 2.59 μg/mL.

Conclusion

LRP-1-targeted Lf-LNT-PEG-CS-NCs significantly enhanced intranasal brain delivery, cellular uptake, and apoptotic activity of LNT, demonstrating a promising noninvasive platform for targeted GBM therapy.

Read PDF

Similar papers

Sep 2026

Synthesis and characterization of l-arginine-grafted chitosan nanoparticles for intranasal Dasatinib delivery and brain targeting.

Glioblastoma (GBM) remains a highly aggressive brain malignancy with limited therapeutic success owing to poor drug accumulation and restricted brain delivery. Dasatinib (DTB), a tyrosine kinase inhibitor with anticancer potential, is limited by poor solubility and brain penetration. This study developed l-arginine-gra...

Mansi Thakur, Aditi Sonone, Sagar S. Trivedi et al. · 0 citations
Open access Oct 2026

Engineered solid lipid-polymer hybrid nanoparticles for trackable co-delivery of glycoalkaloids and Bcl-2/CD146-targeting of siRNAs: A topical formulation strategy for melanoma.

The molecular complexity and adaptive resistance of melanoma limit the efficacy of conventional monotherapies, driving the development of multimodal therapeutic strategies. Here, we report the design and characterization of solid lipid-polymer hybrid nanoparticles (SLPHs) incorporating a FITC-labeled cationic polymer a...

Y. G. Gonçalves, Breno H. Martinez, L. O. Sousa et al. · 0 citations
Open access Oct 2026

Tricin‐Loaded Liposomes as a Passive Targeting Nanodelivery System for Enhanced Gastric Cancer Therapy

Gastric cancer (GC) has a poor prognosis. Chemotherapy causes severe systemic toxicity, and only a small subset of patients benefits from HER2/PD‑L1‑targeted therapies. Tricin (TRI), a natural flavonoid with anti‑GC activity, is limited by poor water solubility and low bioavailability. This study aimed to construct TRI...

Bai-Ji Cui, Hong-Mei Zhang, Hao Wu et al. · 0 citations
Oct 2026

Gemcitabine Delivery and Nucleolin-Targeting Nanocarriers Based on N6L-Functionalized Polyelectrolyte Complexes and Layer-By-Layer Lipid Nanoparticles.

Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to chemotherapy due to dense stromal barriers. Although gemcitabine remains the standard treatment, its efficacy is limited. Combining it with the pseudopeptide N6L has shown synergistic effects, but administering them individually in biological systems poses...

L. Larue, Blandine Brissault, Cléa Chesneau et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.